Keywords: amylin, exendin-4, shows, promise, ph, ii, pharmaceuticals
Amylin's exendin-4 shows promise in Ph II
Article | 11 January 2000
Amylin Pharmaceuticals says that lower doses of its antidiabetic drugAC2993 (synthetic exendin-4) demonstrated significant glucose-lowering effects and a reduced incidence ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
